Tromboembolismo venoso no climatério
Palavras-chave:
climatério, trombose venosa, embolia pulmonar, segurança, estrogênios, progesteronaResumo
O tromboembolismo venoso (TEV) é um evento incomum antes da menopausa, mas com incidência aumentada durante e após esse período. A terapia de reposição hormonal (TRH) é um importante fator de risco adicional para TEV nas mulheres no climatério e está associada ao uso de estrogênio oral isolado ou em combinação com progestagênios, sendo a via transdérmica considerada segura. Apesar de dados recentes apontarem uma má relação riscos versus benefícios em mulheres submetidas à TRH, muitas ainda recebem prescrição de estrógenos para minimizar os sintomas do climatério e de progestagênios para neutralizar o risco de câncer de endométrio, sem estratificação do risco de TEV.
Referências
Canonico M. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Maturitas. 2015;82(3):304-7.
Oger E. Incidence of Venous Thromboembolism: A Community-based Study in Western France. Thromb Haemost. 2000;83(05):657-60.
Scarabin P-Y. Hormone therapy and venous thromboembolism among postmenopausal women. Front Horm Res. 2014;43:21-32.
Anderson FA, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933-8.
Olié V, et al. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol. 2010;17(5):457-63.
Royal College of Obstetricians & Gynaecologists. Thromboembolic Disease in Pregnancy and the Puerperium: Acute Management [Green-top Guideline No. 37b]; 2015 [acesso em 22 Jun 2018]. Disponível em: https://www.rcog.org.uk/globalassets/documents/guidelines/gtg-37b.pdf.
Marjoribanks J, et al. Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev. 2017;1:CD004143.
Rossouw JE, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33.
Canonico M, et al. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas. 2011;70(4):354-60.
Canonico M, et al. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ. 2008;336(7655):1227-31.
Hulley S. Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal Women. JAMA. 1998;280(7):605.
Høibraaten E, et al. Increased Risk of Recurrent Venous Thromboembolism during Hormone Replacement Therapy. Thromb Haemost. 2000;84(12):961-7.
Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, Sidney S, Rosendaal FR: Estrogen plus progestin and risk of venous thrombosis. JAMA 2004; 292:1573-1580.
Curb JD, et al. Venous Thrombosis and Conjugated Equine Estrogen in Women Without a Uterus. Arch Intern Med. 2006;166(7):772.
Vickers MR, et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomized controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335(7613):239.
Daly E, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348(9033):977-80.
Høibraaten E, et al. Hormone replacement therapy with estradiol and risk of venous thromboembolism: a population-based case-control study. Thromb Haemost. 1999;82(4):1218-21.
Gutthann SP, et al. Hormone replacement therapy and risk of venous thromboembolism: population-based case-control study. Maturitas. 1997;314(7083):293.
Douketis JD, et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost. 2005;3(5):943-8.
Scarabin P-Y, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362(9382):428-32.
Canonico M, et al. Hormone Therapy and Venous Thromboembolism Among Postmenopausal Women: Impact of the Route of Estrogen Administration and Progestogens: The ESTHER Study. Circulation. 2007;115(7):840-5.
Canonico M, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arteriosclerosis, Thrombosis, and Vascular Biology. 2010a;30(2):340-5.
Renoux C, et al. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost. 2010;8(5):979-86.
Sweetland S, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10(11):2277-86.
Roach REJ, et al. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost. 2013;11(1):124-31.
Olié V, et al. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause. 2011;18(5):488-93.
Scarabin P-Y, et al. Increased thrombin generation among postmenopausal women using hormone therapy: importance of the route of estrogen administration and progestogens. Menopause. 2011;18(8):873-9.
Oger E. Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial. Arterioscler Thromb Vasc Biol. 2003;23(9):1671-6.
Scarabin P-Y, et al. Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Blood Coagulation and Fibrinolysis in Postmenopausal Women: A Randomized Controlled Trial. Arterioscler Thromb Vasc Biol. 1997;17(11):3071-8.
Canonico M, et al. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause. 2010b;17(6):1122-7.
Tremollieres F, et al. EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas. 2011;69(2):195-8.
North American Menopause Society. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause. 2012;19(3):257-71.
